ABCA1 and early-onset autosomal dominant Alzheimer disease: LXR signalling impacts the development of Alzheimer’s disease (AD) pathology and LXRs are promising therapeutic targets for AD treatment because of their ability to affect components of the disease such as cholesterol content, Aβ clearance, APP processing, ABCA1, etc. [52].